Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Louise Garside"'
Autor:
Parul Patel, Susan L. Ford, Mark Baker, Claudia Meyer, Louise Garside, Ronald D'Amico, Rodica Van Solingen‐Ristea, Herta Crauwels, Joseph W. Polli, Ciara Seal, Itziar Yagüe Muñoz, Shanker Thiagarajah, Eileen Birmingham, William R. Spreen, Bryan Baugh, Jean van Wyk, Vani Vannappagari
Publikováno v:
HIV Medicine. 24:568-579
Limited data exist on pregnant women living with HIV exposed to cabotegravir + rilpivirine (CAB + RPV). Outcomes in pregnant participants exposed to CAB + RPV, and pharmacokinetic washout data in those exposed to CAB + RPV long-acting (LA) with live
Autor:
Parul Patel, Emilie Elliot, Ronald D’Amico, Louise Garside, Conor Smith, Jeremy Roberts, Joseph W Polli, Moti Ramgopal, Princy N Kumar, Olayemi Osiyemi, Bryan Baugh, Jean A van Wyk
Publikováno v:
Open Forum Infectious Diseases. 9
Background Long-acting cabotegravir + rilpivirine (CAB + RPV LA) administered monthly or every 2 months is the first and only complete LA regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. This post hoc an
Autor:
Margaret Gartland, Pedro Cahn, Edwin DeJesus, Ricardo Sobhie Diaz, Robert Grossberg, Michael Kozal, Princy Kumar, Jean-Michel Molina, Fernando Mendo Urbina, Marcia Wang, Fangfang Du, Shiven Chabria, Andrew Clark, Louise Garside, Mark Krystal, Frank Mannino, Amy Pierce, Peter Ackerman, Max Lataillade
Publikováno v:
Antimicrobial agents and chemotherapy. 66(6)
In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained rates of virologic suppression through 96 weeks. HIV-1 RNA40 copies/mL was
Autor:
Babafemi O Taiwo, Darrell Tan, Parul Patel, Paula Teichner, Joseph Polli, Louise Garside, Ronald D’Amico, Christine L Talarico, Rodica Van Solingen-Ristea, Bryan Baugh, William Spreen, Michael Aboud, Matthew Bosse
Publikováno v:
Open Forum Infectious Diseases
Background Cabotegravir (CAB) plus rilpivirine (RPV) is the first complete long-acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. CAB+RPV LA dosed every 4 weeks (Q4W) or every 8 weeks (Q8W) de